+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

HIV Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Study Design (Interventional, Expanded Access), by Sponsor, by Region, and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 98 Pages
  • July 2022
  • Region: Global
  • Grand View Research
  • ID: 5644946
Description Jump to:
The global HIV clinical trials market size is expected to reach USD 2.1 billion by 2030. It is expected to expand at a CAGR of 6.3% from 2022 to 2030. The main drivers of this market are increasing HIV vaccine trials, increased R&D activities for HIV clinical trials, and rising HIV infection awareness, which leads to a large number of patients enrolling in clinical trials. During the COVID-19 pandemic, there was a halt in the market growth.

This decrease in HIV and AIDS clinical trials is due to stay-at-home orders by the government to prevent COVID-19 that led to canceled and delayed trials. It also includes disruption in patient recruitment, hurdles in the conduction of clinical trials, and rapid study for the development of vaccines and medical products for the prevention of COVID-19 that lead to detrimental effects in HIV clinical trial studies. However, these impacts were significantly reduced by adopting strategic measures taken by the clinical trial conducting organization, regulatory authorities, and government bodies.

According to the WHO, in 2020, there were around 37.7 million people infected with HIV infection. To reduce this number, increasing funding and partnerships by biotechnology and pharmaceutical firms have been observed. Moreover, increasing initiatives are being taken by the government to find treatment and spread awareness regarding this disease. For instance, in October 2021, Samsung BioLogics collaborated with Enzolytics Inc. This partnership aims to manufacture Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies.

However, a lack of awareness regarding HIV clinical research trials and the availability of treatments for preventing it are factors that are hindering the growth of this market. According to a report by BioMed Central Ltd. in Europe, out of 467 participants, about one-third of them were not aware of the HIV infection. As a result, ignorance and unawareness regarding the disease will prevent admission to an HIV clinical trial.

HIV Clinical Trials Market Report Highlights

  • Based on phase, the phase I segment held the largest revenue share of over 30.0% in 2021. In this segment, safety, tolerability, and pharmacokinetics of the drug are accessed
  • By study design, the expanded access studies segment is expected to expand at the fastest CAGR of 6.4% over the forecast period. This is due to the rising innovation in this area
  • North America dominated the market with a revenue share of over 45.0% in 2021. This can be attributed to several citizens being infected with multiple strains of HIV in this region. Due to this, multiple companies are investing in vaccine development to prevent HIV

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Product
1.1.2 Nutrients
1.1.3 Regional Scope
1.1.4 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective - 1:
1.10.2 Objective - 2:
1.10.3 Objective - 3:
1.10.4 Objective - 4:
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 HIV Clinical Trials Market: Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Variable Analysis
3.2.1 Market Driver Analysis
3.2.1.1 Rising Drug Approvals And New Product Launches
3.2.1.2 Increasing R&D Initiatives By Biotechnology & Pharmaceutical Companies
3.2.1.3 Increasing Incidence Of HIV
3.2.2 Market Restraint Analysis
3.2.2.1 Lack of awareness and access to treatment for HIV Infection
3.2.2.2 Stringent regulations
3.3 Penetration & Growth Prospect Mapping
3.4 HIV Clinical Trials Market: Analysis Tools
3.4.1 Pestel Analysis
3.4.2 Porter’s Five Forces Analysis
3.5 COVID- 19 Impact on HIV Clinical Trials Market
Chapter 4 HIV Clinical Trials Market: Phase Segment Analysis
4.1 HIV Clinical Trials: Market Share Analysis, 2021&2030
4.2 Phase I
4.2.1 Phase I market, 2018 - 2030 (USD Million)
4.3 Phase II
4.3.1 Phase II market, 2018 - 2030 (USD Million)
4.4 Phase III
4.4.1 Phase III market, 2018 - 2030 (USD Million)
4.5 Phase IV
4.5.1 Phase IV market, 2018 - 2030 (USD Million)
Chapter 5 HIV Clinical Trials Market: Study Design Segment Analysis
5.1 HIV Clinical Trials: Market Share Analysis, 2021 & 2030
5.2 Interventional studies
5.2.1 Interventional studies market, 2018 - 2030 (USD Million)
5.3 Observational studies
5.3.1 Observational studies market, 2018 - 2030 (USD Million)
5.4 Expanded access studies
5.4.1 Expanded access studies market, 2018 - 2030 (USD Million)
Chapter 6 HIV Clinical Trials Market: Sponsor Segment Analysis
6.1 HIV Clinical Trials: Market Share Analysis, 2021 & 2030
6.2 Pharmaceutical & biopharmaceutical companies
6.2.1 Pharmaceutical & biopharmaceutical companies market, 2018 - 2030 (USD Million)
6.3 Non-Profit Organizations
6.3.1 Non-Profit Organizations market, 2018 - 2030 (USD Million)
6.4 Others
6.4.1 Others market, 2018 - 2030 (USD Million)
Chapter 7 HIV Clinical Trials Market: Regional Analysis
7.1 HIV Clinical Trials: Market Share Analysis, 2021 & 2030
7.2 North America
7.2.1 North America HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.2.3 Canada
7.2.3.1 Canada HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.3 Europe
7.3.1 Europe HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.3.2 U.K.
7.3.2.1 U.K. HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.3.3 Germany
7.3.3.1 Germany HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.3.4 France
7.3.4.1 France HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.3.5 Italy
7.3.5.1 Italy HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.3.6 Spain
7.3.6.1 Spain HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.4.2 Japan
7.4.2.1 Japan HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.4.3 China
7.4.3.1 China HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.4.4 India
7.4.4.1 India HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.4.5 Thailand
7.4.5.1 Thailand HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.4.6 South Korea
7.4.6.1 South Korea HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.5.3 Mexico
7.5.3.1 Mexico HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.5.4 Argentina
7.5.4.1 Argentina HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.5.5 Colombia
7.5.5.1 Colombia HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.6 MEA
7.6.1 MEA HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia HIV Clinical Trials market, 2018 - 2030 (USD Million)
7.6.4 UAE
7.6.4.1 UAE HIV Clinical Trials market, 2018 - 2030 (USD Million)
Chapter 8 Company Profiles
8.1 Company Profiles
8.1.1 PPD Inc.
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic initiatives
8.1.2 IQVIA Inc.
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Parexel International Corporation.
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic initiatives
8.1.4 ICON plc
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic initiatives
8.1.5 Syneos Health
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic initiatives
8.1.6 WuXi AppTec
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Product benchmarking
8.1.6.4 Strategic initiatives
8.1.7 Janssen Global Services, LLC
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic initiatives
8.1.8 Gilead Sciences, Inc.
8.1.8.1 Company overview
8.1.8.2 Product benchmarking
8.1.8.4 Strategic initiatives
8.1.9 Bionor Holding AS
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic initiatives
8.1.10 Charles River Laboratories
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic initiatives
8.1.11 GSK plc.
8.1.11.1 Company overview
8.1.11.2 Financial performance
8.1.11.3 Product benchmarking
8.1.11.4 Strategic initiatives
8.1.12 SGS SA
8.1.12.1 Company overview
8.1.12.2 Financial performance
8.1.12.3 Product benchmarking
8.1.12.4 Strategic initiatives
List of Tables
Table 1 Global HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 2 Global HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 3 Global HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 4 Global HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 5 North America HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 6 North America HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 7 North America HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 8 North America HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 9 U.S. HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 10 U.S. HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 11 U.S. HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 12 U.S. HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 13 Canada HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 14 Canada HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 15 Canada HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 16 Canada HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 17 Europe HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 18 Europe HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 19 Europe HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 20 Europe HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 21 U.K. HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 22 U.K. HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 23 U.K. HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 24 U.K. HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 25 Germany HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 26 Germany HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 27 Germany HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 28 Germany HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 29 France HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 30 France HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 31 France HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 32 France HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 33 Italy HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 34 Italy HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 35 Italy HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 36 Italy HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 37 Spain HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 38 Spain HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 39 Spain HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 40 Spain HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 41 Asia Pacific HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 42 Asia Pacific HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 43 Asia Pacific HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 44 Asia Pacific HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 45 Japan HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 46 Japan HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 47 Japan HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 48 Japan HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 49 India HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 50 India HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 51 India HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 52 India HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 53 China HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 54 China HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 55 China HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 56 China HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 57 Thailand HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 58 Thailand HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 59 Thailand HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 60 Thailand HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 61 South Korea HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 62 South Korea HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 63 South Korea HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 64 South Korea HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 65 Latin America HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 66 Latin America HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 67 Latin America HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 68 Latin America HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 69 Mexico HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 70 Mexico HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 71 Mexico HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 72 Mexico HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 73 Brazil HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 74 Brazil HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 75 Brazil HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 76 Brazil HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 77 Argentina HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 78 Argentina HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 79 Argentina HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 80 Argentina HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 81 Colombia HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 82 Colombia HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 83 Colombia HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 84 Colombia HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 85 MEA HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 86 MEA HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 87 MEA HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 88 MEA HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 89 South Africa HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 90 South Africa HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 91 South Africa HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 92 South Africa HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 93 Saudi Arabia HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 94 Saudi Arabia HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 95 Saudi Arabia HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 96 Saudi Arabia HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
Table 97 UAE HIV clinical trials market, by region, 2018-2030 (USD Million)
Table 98 UAE HIV clinical trials market, by phase, 2018-2030 (USD Million)
Table 99 UAE HIV clinical trials market, by study design, 2018-2030 (USD Million)
Table 100 UAE HIV clinical trials market, by sponsor, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity Flow Analysis
Fig. 9 Volume Price Analysis
Fig. 10 HIV Clinical Trials market snapshot (2021)
Fig. 11 Market trends and outlook
Fig. 12 HIV Clinical Trials market segmentation
Fig. 13 Market driver relevance analysis (Current & future impact)
Fig. 14 Market restraint relevance analysis (Current & future impact)
Fig. 15 Penetration & growth prospect mapping
Fig. 16 SWOT analysis, by a factor (political & legal, economic and technological)
Fig. 17 PORTER’S ANALYSIS
Fig. 18 HIV Clinical Trials market phase outlook: Segment dashboard
Fig. 19 HIV Clinical Trials market: Phase movement analysis
Fig. 20 Phase I market, 2018-2030 (USD Million)
Fig. 21 Phase II market, 2018-2030 (USD Million)
Fig. 22 Phase III market, 2018-2030 (USD Million)
Fig. 23 Phase IV market, 2018-2030 (USD Million)
Fig. 24 HIV Clinical Trials market study design outlook: Segment dashboard
Fig. 25 HIV Clinical Trials market: Study Design movement analysis
Fig. 26 Interventional studies market, 2018-2030 (USD Million)
Fig. 27 Observational studies market, 2018-2030 (USD Million)
Fig. 28 Expanded access studies market, 2018-2030 (USD Million)
Fig. 29 HIV Clinical Trials market sponsor outlook: Segment dashboard
Fig. 30 HIV Clinical Trials market: Sponsor movement analysis
Fig. 31 Pharmaceutical & biopharmaceutical companies market, 2018-2030 (USD Million)
Fig. 32 Non-Profit Organizations market, 2018-2030 (USD Million)
Fig. 33 Others market, 2018-2030 (USD Million)
Fig. 34 Regional marketplace: Key takeaways
Fig. 35 Regional outlook, 2021&2030
Fig. 36 North America market, 2018-2030 (USD Million)
Fig. 37 U.S. market, 2018-2030 (USD Million)
Fig. 38 Canada market, 2018-2030 (USD Million)
Fig. 39 Europe market, 2018-2030 (USD Million)
Fig. 40 U.K. market, 2018-2030 (USD Million)
Fig. 41 Germany market, 2018-2030 (USD Million)
Fig. 42 France market, 2018-2030 (USD Million)
Fig. 43 Italy market, 2018-2030 (USD Million)
Fig. 44 Spain market, 2018-2030 (USD Million)
Fig. 45 Asia Pacific market, 2018-2030 (USD Million)
Fig. 46 Japan market, 2018-2030 (USD Million)
Fig. 47 China market, 2018-2030 (USD Million)
Fig. 48 India market, 2018-2030 (USD Million)
Fig. 49 Thailand market, 2018-2030 (USD Million)
Fig. 50 South Korea market, 2018-2030 (USD Million)
Fig. 51 Latin America market, 2018-2030 (USD Million)
Fig. 52 Brazil market, 2018-2030 (USD Million)
Fig. 53 Mexico market, 2018-2030 (USD Million)
Fig. 54 Argentina market, 2018-2030 (USD Million)
Fig. 55 Colombia market, 2018-2030 (USD Million)
Fig. 56 MEA market, 2018-2030 (USD Million)
Fig. 57 South Africa market, 2018-2030 (USD Million)
Fig. 58 Saudi Arabia market, 2018-2030 (USD Million)
Fig. 59 UAE market, 2018-2030 (USD Million)

Companies Mentioned

  • PPD Inc.
  • IQVIA Inc.
  • Parexel International Corporation.
  • ICON plc
  • Syneos Health
  • WuXi AppTec
  • Janssen Global Services, LLC
  • Gilead Sciences, Inc.
  • Bionor Holding AS
  • Charles River Laboratories
  • GSK plc.
  • SGS SA

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages98
PublishedJuly 2022
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 1.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.1 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

HIV Clinical Trials Market by Phase, Study Design, Type of Intervention, Participant, Sponsor - Global Forecast 2025-2030 - Product Image

HIV Clinical Trials Market by Phase, Study Design, Type of Intervention, Participant, Sponsor - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
HIV Vaccines Market by Phase, Category, Antibodies, End Users - Global Forecast 2025-2030 - Product Image

HIV Vaccines Market by Phase, Category, Antibodies, End Users - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
HIV-associated Lipodystrophy - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

HIV-associated Lipodystrophy - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Clinical Trials Support Services Market Size, Share and Trends Analysis Report by Phase (Phase I, Phase III), Service, Sponsor (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies), and Region 2024-2030 - Product Image

Clinical Trials Support Services Market Size, Share and Trends Analysis Report by Phase (Phase I, Phase III), Service, Sponsor (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies), and Region 2024-2030

  • Report
  • 130 Pages
  • Global
From
Europe Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II), Indication (Oncology, Diabetes), Study Design, Service Type, Sponsor, Region, and Segment Forecasts, 2025-2030 - Product Image

Europe Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II), Indication (Oncology, Diabetes), Study Design, Service Type, Sponsor, Region, and Segment Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Europe
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.